However, in NSHPT (due to homozygous or compound heterozygous mutations in CaSR), therapeutic interventions must aim to lower calcium and PTH levels until a diagnosis is established and a definite (surgical) treatment can be pursued. The gene discussed is PTH; the disease is neonatal severe primary hyperparathyroidism.